Literature DB >> 9620722

Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene.

Q Mei, S Gurunathan, H Masur, J A Kovacs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9620722     DOI： 10.1016/S0140-6736(05)77687-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  21 in total

1.  Genetic analysis of multiple loci suggests that mutations in the Pneumocystis carinii f. sp. hominis dihydropteroate synthase gene arose independently in multiple strains.

Authors:  L Ma; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  A Quantitative Model to Estimate Drug Resistance in Pathogens.

Authors:  Frazier N Baker; Melanie T Cushion; Aleksey Porollo
Journal:  J Fungi (Basel)       Date:  2016-12-05

3.  Development and evaluation of a molecular viability assay for Pneumocystis carinii.

Authors:  N Maher; S Vermund; M Lasbury; C Lee; M Bartlett; T R Unnasch
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy.

Authors:  T Takahashi; N Hosoya; T Endo; T Nakamura; H Sakashita; K Kimura; K Ohnishi; Y Nakamura; A Iwamoto
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds.

Authors:  Melanie T Cushion; Peter D Walzer; Margaret S Collins; Sandra Rebholz; Jean Jacques Vanden Eynde; Annie Mayence; Tien L Huang
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.

Authors:  Peter Iliades; Steven R Meshnick; Ian G Macreadie
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 7.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission.

Authors:  C B Beard; J L Carter; S P Keely; L Huang; N J Pieniazek; I N Moura; J M Roberts; A W Hightower; M S Bens; A R Freeman; S Lee; J R Stringer; J S Duchin; C del Rio; D Rimland; R P Baughman; D A Levy; V J Dietz; P Simon; T R Navin
Journal:  Emerg Infect Dis       Date:  2000 May-Jun       Impact factor: 6.883

9.  Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis.

Authors:  E Calderón; C de la Horra; F J Medrano; A López-Suárez; M A Montes-Cano; N Respaldiza; J Elvira-González; J Martín-Juan; A Bascuñana; J M Varela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-03       Impact factor: 3.267

10.  Clinical significance and phylogenetic relationship of novel Australian Pneumocystis jirovecii genotypes.

Authors:  Sebastiaan J van Hal; Felix Gilgado; Tom Doyle; Joel Barratt; Damien Stark; Wieland Meyer; Jock Harkness
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.